Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY ) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief...
Incyte (INCY) Q4 Earnings Miss Estimates
Incyte (INCY) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.06 per share a year ago.
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Incyte (INCY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
– U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal da...
Incyte: Multiple Drug Launches Bode Well For Future Growth
Incyte's robust growth, led by JAKAFI and OPZELURA, is set to increase with new product launches of MONJUVI, ZYNZY, and NIKTIMVO in 2025. Analysts expect Incyte's revenues to grow by ~10% annually ...
INCY vs. VRTX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the ...
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals
INCY's phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer, meets primary and secondary endpoints.
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients w...
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in NSCLC.
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.
Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study
Incyte (INCY) led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.
Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock.
The biopharmaceutical company provided disappointing updates on two research studies.
Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. New product approvals, like Niktimvo, should diversify Incyte's revenue and reduc...
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.
Related Companies